This is a pilot trial to examine the acceptability and feasibility of time-restricted eating as an adjunct to medication treatment for bipolar disorder.
Time-restricted eating (TRE) is a way of scheduling food intake that has been shown to improve circadian rhythms in animals and humans. TRE is based on animal and human science that shows that the timing of eating powerfully influences diurnal rhythms. Animal research has shown that feeding during sleep periods leads to a surge of norepinephrine, cortisol, wakefulness, and activity. Drawing on this, over a decade of studies have examined the impact of experimentally randomizing mice to time-restricted feeding during wake hours (vs. 24-hour ad libitum feeding). Importantly, caloric intake and other facets of diet were yoked for strict control. A consistent finding is that TRE had powerful benefits for circadian and metabolic indicators across studies,and more recent data also shows benefit for animal longevity. Here, the investigators' goal is to extend this work to bipolar disorder (BD). More specifically, the investigators will gather data to examine the acceptability and feasibility of TRE among those who self-identify with bipolar disorder and who experience some problems with sleep, circadian rhythms, or schedules. The investigators will gather measures of mania, depression, sleep, and QOL, to provide preliminary evidence of change on these dimensions.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
1
Restrict eating to a 10-hour window.
University of California
Berkeley, California, United States
Acceptability as assessed using self-ratings on items designed for this study
self-ratings of the acceptability of the intervention
Time frame: Immediately post-treatment (10 weeks)
Feasibility as assessed by percent of clients who complete the assessments and intervention
Percentage of clients who do not drop out of the trial. Drop out would be defined as not completing the TRE intervention, or failing to complete the end-of-treatment intervention.
Time frame: Immediately post-treatment (10 weeks)
Lower Mania symptoms as assessed with the Patient Mania Questionnaire-9
Self-Rated Patient Mania Questionnaire-9
Time frame: Change from baseline to immediately post-treatment (10 weeks)
Lower Depression symptoms as assessed with the Patient Health Questionnaire-9
PHQ-9
Time frame: Change from baseline to immediately post-treatment (10 weeks)
Lower scores on two Patient Reported Outcome Measurement Information System (PROMIS) sleep scales
PROMIS self-report of sleep disturbance and sleep-related impairment (summed together)
Time frame: Change from baseline to immediately post-treatment (10 weeks)
higher scores on Self-rated Quality of Life
Brief Quality of Life in Bipolar Disorder scale
Time frame: Change from baseline to immediatly post-treatment (10 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.